Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination (Q27008256)

Martine Goossens

series ordinal

2

1 reference

Katia Pauwels

series ordinal

3

1 reference

Didier Breyer

series ordinal

4

1 reference

language of work or name

1 reference

30 March 2012

1 reference

1 reference

30

1 reference

PubMed

issue

16

1 reference

PubMed

page(s)

2623-32

1 reference

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

The orthopoxvirus 68-kilodalton ankyrin-like protein is essential for DNA replication and complete gene expression of modified vaccinia virus Ankara in nonpermissive human and murine cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Introduction of the Six Major Genomic Deletions of Modified Vaccinia Virus Ankara (MVA) into the Parental Vaccinia Virus Is Not Sufficient To Reproduce an MVA-Like Phenotype in Cell Culture and in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Partial deletion of the human host range gene in the attenuated vaccinia virus MVA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Nonreplicating vaccinia vector efficiently expresses recombinant genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Smallpox vaccines: Past, present, and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Cytoplasmic organization of POXvirus DNA replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

MVA as a vector for vaccines against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

A comparison of IFNgamma detection methods used in tuberculosis vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Genetic stability of recombinant MVA-BN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Intragenic and intergenic recombination between temperature-sensitive mutants of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Effects of DNA structure and homology length on vaccinia virus recombination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Poxviruses as vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Identification of potentially hazardous human gene products in GMO risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Transient host range selection for genetic engineering of modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

An inventory of shedding data from clinical gene therapy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016

High-frequency homologous recombination in vaccinia virus DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.016